Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New therapy aims to heal Veterans' moral wounds from war

NCT ID NCT03764033

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a therapy called Impact of Killing (IOK) for veterans with PTSD caused by moral injury—distress from killing or being responsible for a death in war. One hundred veterans received either IOK or a standard PTSD therapy over 10 sessions. The goal was to see if IOK improves quality of life and reduces PTSD symptoms, with a six-month follow-up to check if benefits last.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Impact of Killing (IOK) therapy
What this could lead to
If it works, this could offer a new therapy option for veterans with PTSD from moral injury, improving their quality of life and reducing symptoms.
What could go wrong
This is a completed trial with 100 participants, so results are available but may not apply to all veterans. The therapy is behavioral and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Aug 2019

Finished

Dec 2024

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 82 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Veterans 18-82 years of age * Veterans who meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for Post-traumatic Stress Disorder (PTSD) or score 23 or higher on the Clinician-Administered PTSD Scale for DSM-5 (CAPS) screening interview. * Veterans who endorsed killing or being responsible for the death of another in a war zone and report continued distress regarding these events * Distress will be operationalized by a positive response to one or more of the nine self-directed moral injury items on the Expressions of Moral Injury Scale-Military Version (EMIS-M) or item #4 on the Moral Injury Events Scale (MIES) * Veterans who have initiated or completed an evidence-based treatment for PTSD, such as Cognitive Processing Therapy (CPT) or Prolonged Exposure (PE) * If receiving CPT or PE, Veterans must complete treatment and wait two weeks prior to screening * If receiving prescription medication for PTSD, Veterans must be one month stable on medication and not make any changes to medication during the course of the active treatment phase of the study Exclusion Criteria: * Veterans with current or lifetime diagnosis of a psychotic disorder or current untreated/unmanaged mania. * Veterans with recent suicidal or homicidal behaviors (chronic suicidal ideation is not exclusionary) * Veterans with recent psychiatric hospitalizations * Veterans with moderate or severe alcohol or drug dependence within the past three months * Veterans receiving individual therapy for PTSD or those planning to start skills-based or trauma-focused group psychotherapy will be excluded * However, these Veterans will be offered the opportunity to be screened again after completion of individual PTSD therapy or once they are three months stable in group treatment, with no plans to discontinue this treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Moral injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Durham VA Medical Center, Durham, NC

    Durham, North Carolina, 27705, United States

  • James J. Peters VA Medical Center, Bronx, NY

    The Bronx, New York, 10468, United States

  • San Francisco VA Medical Center, San Francisco, CA

    San Francisco, California, 94121-1563, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.